Effect of aripiperazole on psychiatric symptoms in patients with Parkinson disease

Effect of aripiperazole on psychiatric symptoms in patients with Parkinson disease - Effect of aripiperazole on PD psychosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007711

Enrollment

Registered

2012-04-12

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

Aripipurazole treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with idiopathic Parkinson disease with hallucination, delusion or both.

Exclusion criteria

Exclusion criteria: Patients accompanied by serious physical condition or disturbed central nervous system functioning which can cause psychosis.

Design outcomes

Primary

Measure	Time frame
BPRS, adverse effect	—

Secondary

Measure	Time frame
UPDRS, CI-I, CGI-S,MMSE,FAB	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026